1st Wave BioPharma acquires ImmunogenX, plans to license latiglutenase for celiac disease treatment after Phase 3 trials.
First Wave BioPharma completes acquisition of ImmunogenX, focusing on advancing a gastrointestinal pipeline. The combined company plans to license commercial rights to latiglutenase, a promising treatment for celiac disease, to a global pharmaceutical company. Latiglutenase has demonstrated effectiveness in Phase 2 trials and Phase 3 clinical trials are expected to begin in early 2025.
March 14, 2024
5 Articles